Story detail view · 2026-07
STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit

STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit

Quick Summary

On analyses that looked at major cardiovascular events, those taking retatrutide did not have a significant lower risk of death, heart attack, or stroke.

Continue Reading on STAT News

Get instant updates on Telegram

Join our channel to receive the latest headlines and breaking stories as soon as they are published.

Join channel

Comments (0)

Join the conversation. Comments are rate-limited, secured, and GDPR-compliant.

No comments yet. Be the first to share your thoughts!

Write a comment

0 / 500